Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress

摘要: Pancreatic ductal adenocarcinoma (PDAC) is one of the major causes death in Western world, and it estimated to become second leading cause tumour-related mortality next 10 years. Among pancreatic cancers, adenocarcinomas are by far most common, characterised a challenging diagnosis due lack initial pathognomonic clinical signs. In this scenario, non-metastatic locally advanced cancer (LAPC) accounts for large proportion all new diagnoses. There no consensus on common definition LAPC. Still, usually includes tumours that not resectable vascular involvement. As today, treatment limited, prognosis very unfavourable. Curative-intent surgery remains gold-standard even if often jeopardized Continuing progress our understanding LAPC genetics immunology will permit development different treatments, targeted or combined, including radiation therapy, hadrontherapy, immunotherapies chemotherapies. A multidisciplinary approach combining various fields expertise essential aiming limit disease progression as well patient outcome. Using narrative literature review approach, manuscript explores up-to-date knowledge concerning management.